FAM107A

Across TCGA pan-cancer cohorts, FAM107A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM107A data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher FAM107A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM107A expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

GBM, LSCC, and LUAD are the cancer types where FAM107A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.298	0.442	.010	13	view →
LSCC	DFS	Tertile	II,III,IV	0.812	1.000	.020	5	view →
LUAD	OS	Tertile	III,IV	0.839	0.284	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FAM107A–GBM (DFS)

Open the GBM breakdown →